Download alessia melegaro - Dondena

ALESSIA MELEGARO
Curriculum Vitae, May 10th, 2012
DONDENA Centre for Research on Social Dynamics
Università Bocconi
Via Guglielmo Röntgen n. 1
20136 Milan, Italy
www.dondena.unibocconi.it
Phone +39.02.58365383
Fax : +39-02-5836.2798
email: [email protected]
EDUCATION
PhD in Biological Sciences. Ecology & Epidemiology Group, Warwick University, UK. Dissertation title:
Epidemiology, mathematical modelling and economics of S.pneumoniae: assessing the potential impact of
vaccination. Date of PhD Award: 11 July 2005
Research Degree Student. Infectious Disease and Epidemiology Unit, London School of Hygiene and
Tropical Medicine, London, UK. (Awarded an MRC fellowship)
Laurea (with distinction) in Economics (5 year programme). Institute for Quantitative Methods, Bocconi
University, Milan, Italy. Dissertation title: Modelling for the analysis and understanding of M.Tuberculosis
dynamics
CURRENT POSITION
Research Fellow at “Carlo F. Dondena” Centre for Research on Social Dynamics, Bocconi University, Italy
(Since Nov. 2008)
Managment Board, Centre Carlo F Dondena on Social Dynamics, Bocconi University (since March 2011)
Major Areas of Professional Interest
Policy modelling, health and well-being. Mathematical modelling and statistical analysis of infectious
disease data, Economic evaluation of healthcare programs, Designing optimal vaccination programs for
resource poor settings, Demographic trends and the effects on social interactions.
INTERNATIONAL GRANTS & PROJECTS (current position)
ERC-2011-StG (2012-2016) - The impact of DEmographic Changes on Infectious DisEase transmission and
control in middle/low income countries (DECIDE). Euros: 1.21M. PI: A.Melegaro
World Health Organisation (2008-2011) - Optimization of vaccination schedules in low and middle
income countries. Euros: 100K. PI: A. Melegaro
European Communicable Disease Centre (2009-2012) - Vaccine preventable disease modelling in the
European Union and EEA/EFTA - Forecasting the effects of introducing a new vaccine in a national/regional
program countries. Euros 265K. PI P. Manfredi (Pisa University). Management Team Member and Scientific
Responsible: A.Melegaro
CV Alessia Melegaro, Page 1 of 4
European Union FP7 (2008-2011) - Modelling the spread of pandemic influenza and strategies for its
containment and mitigation (FLUMODCONT). Euros: 2.8M. PI A. Pugliese (Trento University). Scientific
Responsible for Bocconi University: A.Melegaro
OTHER PROJECTS (current position)
PRIN Miur (2008 – 2011). Health Technology Assessment (HTA) for the economic evaluation of genetic
tests (Fattore V Leiden, Fattore II e MTHFR) for VTE. In collaboration with CERGAS Bocconi. PI:
R.Tarricone, with A.Compagni
Wyeth (2008). Cost effectiveness analysis of pneumococcal vaccination in Italy. In collaboration with
CERGAS Bocconi. PI: C. Jommi
PREVIOUS WORK EXPERIENCE
2004-2008: Research Scientist - Statistics, Modelling and Economics Department, Health Protection
Agency, Centre for Infections, London, UK. Main activities:
-
Analysis of population contact data to identify European mixing patterns as part of the project
‘Improving Public Health Policy in Europe through the Modelling and Economic Evaluation of
Interventions for the Control of Infectious Diseases’ (POLYMOD – EU FP6).
-
Mathematical modelling and economic analysis of national healthcare interventions (i.e. vaccination,
screening, school closure)
2000-2004: Scientist in the Immunisation Department, Communicable Diseases Surveillance Centre
(CDSC), Public Health Laboratory Service, London.
-
Analysis of public health surveillance datasets, epidemiological and cost-effectiveness analysis of
vaccine preventable diseases, policy evaluation. Participation to the project ‘Pneumococcal disease
in Europe’ (Pnc EURO - EU FP5).
TEACHING
-
Lecturer in Decision Analysis in Healthcare, MIHMEP (2012), Bocconi University
Guest Speaker in Decision Analysis in Healthcare, MIHMEP (2010, 2011), Bocconi University
Guest Speaker in International Demography (2010, 2011), Bocconi University
Lecturer of Epidemiological methods and mathematical modelling, London School of Hygiene and
Tropical Medicine, MSc Course and Summer School (2005, 2006, 2007)
Guest Spekear of Mathematical Modelling, Birmingham University, MSc Course (2004, 2005)
Teaching assistant for Statistics, Pisa University, Undergraduate Course (2000)
PEER REVIEWED PUBLICATIONS
 Van Hoek A.J., Melegaro A., Gay N., Bilcke J., Edmunds W.J. The cost-effectiveness of varicella and
combined varicella and Herpes zoster vaccination programmes in the United Kingdom. Vaccine 2012
Feb 1;30(6):1225-34.
 Choi Y.H., Jit M., Gay N., Andrews N., Waight P.A., Melegaro A., George R., Miller E. 7-valent
pneumococcal conjugate vaccination in England and Wales: is it still beneficial despite high levels of
serotype replacement? PLoS One. 2011;6(10):e26190. Epub 2011 Oct 14.
CV Alessia Melegaro, Page 2 of 4

Melegaro, A.; Jit, M.; Gay, N.; Zagheni, E.; Edmunds, W. J. What types of contacts are important for
the spread of infections? Using contact survey data to explore European mixing patterns. Epidemics, 3,
2011, 143:151

Chaiyakunapruk N, Somkrua R, Hutubessy R, Henao AM, Hombach J, Melegaro A, Edmunds JW,
Beutels P. Cost effectiveness of paediatric pneumococcal conjugate vaccines: a comparative
assessment of decision-making tools. BMC Med. 2011 May 12;9:53.

van Hoek AJ, Melegaro A, Zagheni E, Edmunds WJ, Gay N. Modelling the impact of a combined
varicella and zoster vaccination programme on the epidemiology of varicella zoster virus in England.
Vaccine. 2011 Mar 16;29(13):2411-20.

House T, Baguelin M, Van Hoek AJ, White PJ, Sadique Z, Eames K, Read JM, Hens N, Melegaro A,
Edmunds WJ, Keeling MJ. Modelling the impact of local reactive school closures on critical care
provision during an influenza pandemic. Proc Biol Sci. 2011 Feb 2.

Melegaro A, Choi YH, George R, Edmunds WJ, Miller E, Gay NJ. Dynamic models of pneumococcal
carriage and the impact of the Heptavalent Pneumococcal Conjugate Vaccine on invasive
pneumococcal disease. BMC Infect Dis. 2010 Apr 8;10:90.

van Hoek A J; Gay N; Melegaro A; Opstelten W; Edmunds WJ. Estimating the cost-effectiveness of
vaccination against herpes zoster in England and Wales. Vaccine 2009;27(9):1454-67.

Zagheni E, Billari FC, Manfredi P, Melegaro A, Mossong J, Edmunds WJ.Using time-use data to
parameterize models for the spread of close-contact infectious diseases. Am J Epidemiol. 2008 Nov
1;168(9):1082-90. Epub 2008 Sep 18.

Melegaro A, Choi Y, Pebody R, Gay N. Pneumococcal carriage in United Kingdom families:
estimating serotype-specific transmission parameters from longitudinal data. Am J Epidemiol. 2007 Jul
15;166(2):228-35.

Pitman RJ, Melegaro A, Gelb D, Siddiqui MR, Gay NJ, Edmunds WJ. Assessing the burden of
influenza and other respiratory infections in England and Wales. J Infect. 2007 Jun;54(6):530-8. Epub
2006 Nov 9.

Goldblatt D, Hussain M, Andrews N, Ashton L, Virta C, Melegaro A, Pebody R, George R, Soininen
A, Edmunds J, Gay N, Kayhty H, Miller E. Antibody responses to nasopharyngeal carriage of
Streptococcus pneumoniae in adults: a longitudinal household study. J Infect Dis. 2005 Aug
1;192(3):387-93. Epub 2005 Jun 23.
 Melegaro A, Edmunds WJ, Pebody R, Miller E, George R. The current burden of pneumococcal
disease in England and Wales. J Infect. 2006 Jan;52(1):37-48.
 Hussain M, Melegaro A, Pebody RG, George R, Edmunds WJ, Talukdar R, Martin SA, Efstratiou A,
Miller E. A longitudinal household study of Streptococcus pneumoniae nasopharyngeal carriage in a
UK setting. Epidemiol Infect. 2005 Oct;133(5):891-8.
 Melegaro A, Edmunds WJ. A cost-effectiveness analysis of the 7-valent conjugate vaccine in England
and Wales. Vaccine 2004;22: 4203-4214.
 Melegaro A, Gay NJ, Medley GF. Estimating the transmission parameters of pneumococcal carriage in
household. Epidemiology and Infection 2004;132:433-41.
 Melegaro A, Edmunds WJ. The 23-valent pneumococcal polysaccharide vaccine. Part I- Efficacy of
PPV in the elderly: a comparison of meta-analyses. European Journal of Epidemiology 2004: 19(4) 353363.
 Melegaro A, Edmunds WJ. The 23-valent pneumococcal polysaccharide vaccine. Part II- A costeffectiveness analysis for invasive disease in the elderly. European Journal of Epidemiology 2004: 19(4)
365-375.
 Balmer P, North J, Baxter D, Stanford E, Melegaro A, Kaczmarski EB et al. Measurement and
interpretation of pneumococcal IgG levels for clinical management. Clinical and Experimental
CV Alessia Melegaro, Page 3 of 4
Immunology 2003; 133(3): 364-369.
 George R, Melegaro A. Invasive pneumococcal infection: England and Wales, 2000. Communicable
Disease Report Weekly 2003, 13(21).
 Edmunds WJ, Brisson M, Melegaro A. The potential cost-effectiveness of acellular pertussis booster
vaccination in England and Wales. Vaccine 2002; 20:1316-1330.
PAPERS SUBMITTED AND IN REVISION
 De Cao E., Zagheni E., Manfredi P., Melegaro A. The relative importance of frequency of contacts and
time of exposure for the spread of directly transmitted infections. Submitted to AJE, April 2012.
SELECTION OF PRESENTATIONS AT INTERNATIONAL CONFERENCES
 “Modelling varicella and zoster in Europe: can we cope with the current decision paralysis on mass
immunization?”, Epidemics-3, Third International Conference on Infectious Diseases Dynamics, Boston,
MA, USA, (2011).
 “The role of social contacts on children’s health: Statistical inference on infectious disease data”,
Population Association of America Conference, Washington (2011).
 “Using a mathematical model to evaluate the impact of different PCV schedules: Preliminary results
from the West Africa epidemiological scenario”, Strategic Advisory group of Experts, WHO, Geneva,
Switzerland, (2010)
 “Mathematical modelling for health economic evaluations”, SISMEC National Conference, Padua, Italy
(2009).
 “The cost-effectiveness of pneumococcal vaccination programme”, WHO Global Meeting on
Implementing New and Under-Utilized Vaccines (NUVI), Montreux, Switzerland (2009).
 “The development of an evidence based platform to assist countries with the decision making on
introduction of new vaccines”, WHO and MoPH Thailand Collaborative Consultation Meeting, Bangkok
(2009).
 “The importance of social mixing in the economic evaluation of vaccination programs. The case of
varicella vaccination”, 7th European Conference on Health Economics, Rome, Italy (2008).
 “Estimating age-specific transmission rates for infectious diseases: fitting a survey of contact patterns to
seroprevalence data for VZV and parvovirus B19”, 15th European Conference on Public Health
(EUPHA), Helsinki, Finland (2007).
 “Economic evaluation analysis for developing countries setting”, GAVI Steering Committee, London
(2005).
 “Estimating the biological parameters of pneumococcal carriage in households”, 4th International
Symposium on Pneumococci and Pneumococcal Diseases (ISPPD-4), Helsinki, Finland (2004).
 “Effectiveness and cost-effectiveness of pneumococcal vaccine for invasive disease in the elderly”, 3th
International Symposium on Pneumococci and Pneumococcal Diseases (ISPPD-3), Anchorage, Alaska
(2002).
BOOK
Pandemie d’Italia. Dalla peste nera all’influenza suina: l’impatto sulla società. G.Alfani, A.Melegaro. Con
prefazione di F.Billari. Ed. EGEA 2010.
OTHER ACTIVITIES
Reviewers for journals including: The Lancet, The Paediatric Infectious Disease Journal, American Journal of
Epidemiology, Vaccine, Pharmacoeconomics, European Journal of Epidemiology, Epidemiology and
Infection, PLOS Medicine, Emerging Themes in Epidemiology, BioMed Infectious Diseases, BioMed Public
Health.
CV Alessia Melegaro, Page 4 of 4